The 2nd Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University
Welcome,         Profile    Billing    Logout  
 24 Trials 
55 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Seibold, Frank
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
chen, yan yan
HEARTRIP, NCT03809273: Effects of Yangxinshi Pills on the Exercise Tolerance Compared With Trimetazidine in Patients After PCI

Recruiting
4
668
RoW
Yangxinshi, Trimetazidine, Yangxinshi mimic, Trimetazidine mimic
Shenyang Northern Hospital
Percutaneous Coronary Intervention
12/20
12/20
NCT05481619: Study of the Effect of Vedolizumab on Intestinal Microecological Changes and Its Efficacy in the Treatment of Ulcerative Colitis

Recruiting
4
30
RoW
Vedolizumab
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ulcerative Colitis
01/24
01/24
NCT05205603: Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative Colitis

Recruiting
4
438
RoW
Infliximab, Vedolizumab, Mesalazine
Sixth Affiliated Hospital, Sun Yat-sen University
Ulcerative Colitis, Efficacy, Self, Biologics, Mesalazine
01/24
01/25
TIGER, NCT04255602: A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients

Recruiting
4
2120
RoW
Ticagrelor 60mg, Ticagrelor 90mg
Shanghai Tong Ren Hospital, Shanghai Jiao Tong University School of Medicine, Fudan University
Acute Coronary Syndrome, Coronary Stent Implantation
12/24
12/24
OPTIMA-6, NCT05410925: Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction

Recruiting
4
2260
RoW
Recombinant staphylokinase, Placebo
The First Affiliated Hospital with Nanjing Medical University
ST Elevation Myocardial Infarction
12/26
12/27
LUCENT-1, NCT03518086 / 2017-003229-14: An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

Checkmark Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Oct 2022 - Oct 2022: Full data from P3 LUCENT 1 trial for severe ulcerative colitis
Checkmark Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Feb 2022 - Feb 2022: Efficacy and safety data from LUCENT-1 trial for moderately-to-severely active ulcerative colitis
Checkmark From LUCENT 1 trial for ulcerative colitis
More
Completed
3
1281
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828, Placebo
Eli Lilly and Company
Ulcerative Colitis
01/21
05/24
LUCENT-2, NCT03524092 / 2017-003238-96: A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Checkmark Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
May 2022 - May 2022: Efficacy and safety data of LUCENT-2 in patients with ulcerative colitis
Checkmark Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Dec 2021 - Dec 2021: Safety and efficacy data from LUCENT-2 trial for ulcerative colitis
Active, not recruiting
3
1177
Europe, Canada, Japan, US, RoW
Mirikizumab SC, LY3074828, Mirikizumab IV, Placebo SC
Eli Lilly and Company
Ulcerative Colitis
11/21
12/24
NCT05003245: Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

Recruiting
3
388
RoW
HLX04-O，recombinant anti-vascular endothelial growth factor (VEGF) humanized monoclonal antibody ophthalmic injection, Lucentis
Shanghai Henlius Biotech
Age Related Macular Degeneration
08/23
03/24
TAPER-V, NCT04138706: Initial Vancomycin Taper for the Prevention of Recurrent Clostridium Difficile Infection

Active, not recruiting
3
263
Canada
Vancomycin, Placebos
McGill University Health Centre/Research Institute of the McGill University Health Centre, Canadian Institutes of Health Research (CIHR)
Clostridium Difficile Infection
10/24
10/24
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
NCT06434467: The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma

Not yet recruiting
3
83
RoW
Nelarabine injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
T-lymphoblastic Leukemia, T-lymphoblastic Lymphoma
12/25
05/26
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis

Recruiting
3
368
Europe, US, RoW
SHR0302, Placebo
Reistone Biopharma Company Limited, Reistone Biopharma Company Limited
Ulcerative Colitis
10/24
03/25
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT03221036: Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis

Recruiting
3
402
RoW
Vedolizumab IV, Placebo
Takeda
Moderately to Severely Active Ulcerative Colitis
05/28
07/28
BK2016.01, NCT03146637: Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer

Recruiting
2
80
RoW
Activated CIK, CIK
Benhealth Biopharmaceutical (Shenzhen) Co., Ltd., Beijing 302 Hospital
Advanced Liver Cancer
01/21
01/21
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT04633798: Evaluation of the Efficacy of Intense Pulse Light Combined With Lipiflow in the Treatment of Meibomian Gland Dysfunction

Not yet recruiting
N/A
100
NA
IPL/Lipiflow, IPL/MGX
Aier School of Ophthalmology, Central South University
Meibomian Gland Dysfunction
12/20
12/20
NCT03806621: Rota China Registry

Completed
N/A
980
RoW
Rotational Atherectomy
Beijing Anzhen Hospital, BSC International Medical Trading (Shanghai) Co., Ltd.
Coronary Artery Disease
12/20
01/22
NCT05777616: The Impact of Medication Belief on Adherence to Infliximab in Patients With Crohn's Disease

Completed
N/A
166
RoW
Second Affiliated Hospital, School of Medicine, Zhejiang University
Inflammatory Bowel Diseases
12/21
12/21
NCT05705856: Effectiveness and Safety of Ustekinumab Intensification in Crohn's Disease

Recruiting
N/A
200
RoW
Ustekinumab, UST, Ustekinumab antibody
Second Affiliated Hospital, School of Medicine, Zhejiang University
Crohn Disease
12/23
06/24
NCT06203782: Comparing Endoscopic Strictureplasty vs. Balloon Dilation in Crohn's Strictures

Not yet recruiting
N/A
102
NA
endoscopic stricturoplasty, endoscopic balloon dilation
Second Affiliated Hospital, School of Medicine, Zhejiang University
Crohn Disease
01/26
01/26
NCT04872491: A Study of Vedolizumab in Adults in Real-World Practice

Completed
N/A
500
RoW
Takeda
Colitis, Ulcerative, Crohn Disease
07/24
07/24
NCT05387031: Efficacy of Ustekinumab Therapy in Patients With Symptomatic Stricturing Crohn's Disease

Recruiting
N/A
239
RoW
Ustekinumab, Stelara
Second Affiliated Hospital, School of Medicine, Zhejiang University, Sixth Affiliated Hospital, Sun Yat-sen University, Second Affiliated Hospital of Soochow University, Chongqing Renji Hospital, University of Chinese Academy of Sciences, The First Affiliated Hospital of Zhejiang Chinese Medical University, Seventh Medical Center of PLA Army General Hospital, First People's Hospital of Hangzhou, Yangzhou University, Xian-Janssen Pharmaceutical Ltd.
Crohn Disease, Stricture; Bowel, Intestinal Stricture
08/26
08/27
NCT05638269: A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China

Recruiting
N/A
12000
RoW
no intervention
Zhujiang Hospital, National Natural Science Foundation of China
Essential Hypertension, Liver Cancer, Nasopharyngeal Cancer, Pancreatic Cancer, Lung Cancer, Chronic Kidney Diseases, Acute Coronary Syndrome, Epilepsy, Gastric Cancer, Primary Aldosteronism, Subclinical hypothyroïdism
12/24
12/25
NCT05649488: Evaluate the Safety and Efficacy of Intracoronary Lithotripsy Balloon Catheter and Intracoronary Lithotripsy Apparatus

Recruiting
N/A
184
RoW
Intracoronary lithotripsy balloon catheter and Intracoronary lithotripsy apparatus, Dragonfly Opstar Imaging Catheter
Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
Coronary Artery Disease, Intravascular Lithotripsy
12/24
09/25
CAM Cohort, NCT06798077: Chronic Airway Disease and Miltimorbidity Cohort

Not yet recruiting
N/A
2000
RoW
China-Japan Friendship Hospital, Second Affiliated Hospital of Xi'an Jiaotong University, First Hospital of China Medical University, Henan Provincial People's Hospital, Second Xiangya Hospital of Central South University, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Sichuan University, Ruijin Hospital Affiliated to Shanghai Jiao Tong University, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China
Chronic Obstructive Pulmonary Disease (COPD), Asthma, Bronchiectasis
07/28
07/28
NCT04390971: Safety and Efficacy Evaluation of ET-01 Transplantation in Subjects With Transfusion Dependent β-Thalassaemia

Active, not recruiting
N/A
3
RoW
ET-01
Institute of Hematology & Blood Diseases Hospital, China, EdiGene Inc., The Affiliated Hospital Of Guizhou Medical University, Zunyi Medical College
Transfusion Dependent Beta-Thalassaemia
06/25
08/25
NCT04212494: Thrombus Aspiration in STEMI Patients With High Thrombus Burden

Recruiting
N/A
3838
RoW
Thrombus aspiration, PCI Alone
Guangdong Provincial People's Hospital, Zhongshan People's Hospital, Guangdong, China, Kaiping Central Hospital, The Second Affiliated Hospital of Shantou University Medical College, The Third Xiangya Hospital of Central South University, Sihui City People's Hospital, Shenzhen Baoan District Shiyan People's Hospital, People's Hospital of Nanxiong County, Yuebei People's Hospital, Weifang Medical University, Wuzhou Gongren Hospital, Dafeng Hospital of Chaoyang District in Shantou City, Shenzhen Baoan People's Hospital, Dongguan People's Hospital, Yangchun People's Hospital, Taishan People's Hospital, The Second People's Hospital of Foshan, Guangzhou Hospital of integrated Traditional and West Medicine, Guangning People's Hospital, Foshan Sanshui District People's Hospital, Qingyuan People's Hospital, Luhe County People's Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, The Fourth People's Hospital of Chenzhou, People's Hospital of Dapu County, Shenzhen People's Hospital, Heyuan people's Hospital, Huaiji People's Hospital, People's Hospital of Yingde City, Qingyuan Hospital of Traditional Chinese Medicine Affiliated To Guangzhou University of Traditional Chinese Medicine, Zhongshan Hospital Of Traditional Chinese Medicine, The Third Affiliated Hospital of Guangzhou Medical University, Lianzhou People's Hospital, Lianping Xian Ren Ming Yi Yuan, Guangxi Zhuang Autonomous Region Nationalities Hospital, Liuzhou Municipal Liutie Central Hospital, Chen Zhou 3RD People's Hospital, Longgang District Central Hospital of Shenzhen, The Affiliated Shunde Hospital of Jinan University, Shenzhen Longhua District Central Hospital, Shantou Central Hospital, Tongxiang First People's Hospital, Bobai County People's Hospital, Guangxi, Meizhou Traditional Chinese Medicine Hospital, The Third Affiliated Hospital of Sun Yat-Sen University, Yuedong Hospital, Shenzhen Third People's Hospital, Yangjiang People's Hospital, Jiangmen Central Hospital, Eighth Affiliated Hospital, Sun Yat-sen University, The First People's Hospital of Kashgar Erea, First People's Hospital of Foshan, Zhaoqing Gaoyao People's Hospital, People's Hospital of Nanhai District, Foshan, The Second Affiliated Hospital of Dalian Medical University, Nanning Second People's Hospital, The Second People's Hospital of Nanhai District of Foshan, Shangyou People's Hospital
ST-segment Elevation Myocardial Infarction (STEMI)
08/25
02/26
NCT04912401: the Efficacy and Safety of Etanercept （Yi Sai Pu) in Chinese Patients With Moderate-to-Severe Psoriasis

Recruiting
N/A
100
RoW
Second Affiliated Hospital, School of Medicine, Zhejiang University
Psoriasis, Etanercept
12/25
12/25
NCT05719766: Effect of Incentive Integrated E-IBD Chronic Disease Management Model on the Quality of Life in IBD Patients

Not yet recruiting
N/A
200
RoW
education ,psycological support and social support
Second Affiliated Hospital, School of Medicine, Zhejiang University
Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
01/27
02/27
NCT04933214: Adherence to Exclusive Enteral Nutrition in Patients With Crohn's Disease

Recruiting
N/A
131
RoW
Second Affiliated Hospital, School of Medicine, Zhejiang University
Crohn Disease
12/21
12/21
Biedermann, Luc
ABX464-105, NCT05507203: ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

Recruiting
3
612
Europe, Canada, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
ABTECT, NCT05535946: - Maintenance

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT05488405: Mesalazine Oral Suspension in Active Eosinophilic Esophagitis

Completed
2a
5
Europe
Mesalamine Oral Product, 5-ASA
Dr. Falk Pharma GmbH
Eosinophilic Esophagitis
06/23
07/23
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
ECI-EoE, NCT04769232: Endoscopic Characterisation of Inflammation in EoE

Not yet recruiting
N/A
40
NA
EG-760Z endoscope by Fujifilm
University of Zurich
Eosinophilic Esophagitis
09/21
11/21
NCT05800704: Support of Colonization Resistance of the Gut Microbiota with the Synbiotic Food Supplement Nagasin®

Recruiting
N/A
49
Europe
Nagasin, maltodextrin
University of Zurich, Insel Gruppe AG, University Hospital Bern, Stadtspital Zürich, Kantonsspital Winterthur KSW, Luzerner Kantonsspital, Cantonal Hosptal, Baselland
C. Difficile Enteritis
03/25
03/25
Cichoz-Lach, Halina
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
VARIETY, NCT05384080: A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland

Active, not recruiting
N/A
165
Europe
Takeda
Inflammatory Bowel Disease (IBD), Crohn's Disease, Ulcerative Colitis
08/25
08/25
Niezgoda, Krzysztof
VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis

Active, not recruiting
4
672
Europe, Canada, US, RoW
Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C
Alimentiv Inc., Takeda Development Center Americas, Inc.
Colitis, Ulcerative
03/26
03/26
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
Lee, Choon Kin
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
Craciun, Eugeniu
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
Xia, Xuanping
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27

Download Options